RNS Number : 6733U
Pharma C Investments PLC
27 November 2023

27 November 2023

Pharma C Investments PLC

("Pharma C" or the "Company")

Publication of Circular and Notice of General Meeting

Pharma C (AQSE: PCIL) announces that a general meeting of the Company ("GM") will be held at 11 am on 11 December 2023 at the offices of Hill Dickinson LLP, The Broadgate Tower, 20 Primrose St, London EC2A 2EW. The formal notice of the General Meeting has been posted to all shareholders and is available to download from the Company's website www.pharmacinvestments.com

The purpose of the General Meeting is to propose four resolutions that require shareholder approval.

Ordinary resolutions

Resolution 1: amend the Company's investment policy to allow the Company to consider investments or businesses in the technology, fintech and AI sectors;

Resolution 2: the Directors be generally and unconditionally authorised to exercise all the powers of the Company to allot new ordinary shares of £0.0001 each in the Company (including any rights to subscribe for or convert into such new ordinary shares) up to an aggregate nominal value of £2,281,000;

Special resolutions

Resolution 3: that each existing ordinary share of £0.0025 in the capital of the Company (each an "Existing Ordinary Share") be sub-divided and converted into one ordinary share of £0.0001 and one deferred share of £0.0024 in the capital of the Company.

Resolution 4: that conditional upon the passing of Resolutions 2 and 3, the Directors be empowered to allot equity securities for cash pursuant to the authority conferred by Resolution 2 above as if section 561 of the Companies Act and any pre-emption rights in the Articles did not apply to such allotment.

The Directors of Pharma C take responsibility for this announcement.

For further information please visit www.pharmacinvestments.com

Pharma C Investments	
Gavin Sathianathan, Investment Strategy Director	gavin@pharmacinvestments.com
First Sentinel Corporate Finance	
Brian Stockbridge, Corporate Adviser	+44 20 3855 5551

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services.

For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXBFBBTMTMTTLJ